Mongkolpathumrat, P.; Kijtawornrat, A.; Prompunt, E.; Panya, A.; Chattipakorn, N.; Barrère-Lemaire, S.; Kumphune, S.
Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury. Biomedicines 2021, 9, 422.
https://doi.org/10.3390/biomedicines9040422
AMA Style
Mongkolpathumrat P, Kijtawornrat A, Prompunt E, Panya A, Chattipakorn N, Barrère-Lemaire S, Kumphune S.
Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury. Biomedicines. 2021; 9(4):422.
https://doi.org/10.3390/biomedicines9040422
Chicago/Turabian Style
Mongkolpathumrat, Podsawee, Anusak Kijtawornrat, Eakkapote Prompunt, Aussara Panya, Nipon Chattipakorn, Stephanie Barrère-Lemaire, and Sarawut Kumphune.
2021. "Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury" Biomedicines 9, no. 4: 422.
https://doi.org/10.3390/biomedicines9040422
APA Style
Mongkolpathumrat, P., Kijtawornrat, A., Prompunt, E., Panya, A., Chattipakorn, N., Barrère-Lemaire, S., & Kumphune, S.
(2021). Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury. Biomedicines, 9(4), 422.
https://doi.org/10.3390/biomedicines9040422